ArticleJournal of clinical and translational hepatology2020
Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis.
Abstract read
In one paragraph
Article in Journal of clinical and translational hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Guideline for the prevention and treatment of hepatitis C (2022 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Guideline
- Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Huiying RaoPeking University People's Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China.
Xingxiang YangDepartment of Infectious Diseases, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Youwen TanDepartment of Hepatology, The Third People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China.
Qin NingDepartment of Infectious Diseases, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China.
Daokun YangDepartment of Infectious Diseases, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan, China.
Jiefei WangShanghai Public Health Clinical Center, Shanghai, China.
Yongfeng YangDepartment of Hepatology, The Second Hospital of Nanjing, Nanjing, Jiangsu, China.
Sujun ZhengCenter of Artificial liver, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Dongliang YangDepartment of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jinlin HouDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qing XieDepartment of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Caiyan ZhaoDepartment of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Lunli ZhangDepartment of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Xiaorong MaoDepartment of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Tong SunDepartment of Infectious Diseases, Wuxi Fifth People's Hospital, Wuxi, Jiangsu, China.
Lang BaiInfectious Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Fuchun ZhangDepartment of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China.
Jinglan JinDepartment of Hepato-Biliary-Pancreatic Diseases, The First Hospital of Jilin University, Changchun, Jilin, China.
Yingren ZhaoDepartment of Infectious Diseases, Xi'an Jiaotong University First Affiliated Hospital, Xi'an, Shaanxi, China.
Maorong WangDepartment of Infectious Diseases, DiBaYi Hospital of the Chinese People's Liberation Army, Nanjing, Jiangsu, China.
Wen XieHepatology Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yingjie MaDepartment of Infectious Diseases, Zhengzhou People's Hospital, Zhengzhou, Henan, China.
Jun QuanDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xuebing YanDepartment of Infectious Diseases, Xuzhou Medical College Affiliated Hospital, Xuzhou, Jiangsu, China.
Ping AnDepartment of Infectious Diseases, Shenyang Sixth People's Hospital, Shenyang, Liaoning, China.
Feng LinDepartment of Infectious Diseases, Hainan General Hospital, Haikou, Hainan, China.
Jidong JiaHepatology Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaoxuan HuDepartment of Infectious Diseases, Hunan Provincial People's Hospital, Changsha, Hunan, China.
Zuojiong GongDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Jie WuDepartment of Infectious Diseases, Wuhan central hospital, Wuhan, Hubei, China.
Yongping ChenDepartment of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhansheng JiaDepartment of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University of the People's Liberation Army, Xi'an, Shaanxi, China.
Minghua LinDepartment of Hepatology, Meng Chao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Guiqiang WangDepartment of Infectious Diseases, Peking University First Hospital, Beijing, China.
Yueyong ZhuDepartment of Infectious Diseases, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Yingjun ZhangState Key Laboratory of Anti-Infective Drug Development (NO.2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, China.
Hongming XieState Key Laboratory of Anti-Infective Drug Development (NO.2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, China.
Lin LuoState Key Laboratory of Anti-Infective Drug Development (NO.2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, China.
Qingyun RenState Key Laboratory of Anti-Infective Drug Development (NO.2015DQ780357), Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, China.
Rui HuangPeking University People's Hospital, Peking University Hepatology Institute, National Clinical Research Center for Infectious Disease, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China.
Lai WeiHepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Combination treatmentDirect acting antiviralsEmitasvirGenotype 1Hepatitis C virusSofosbuvir
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.